Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse

International Immunopharmacology

Volumn 10, Issue 7, 2010, Pages 751-759

  Habjanec, Lidija ^a   Halassy, Beata ^a   Tomašić, Jelka ^a  

^a INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Adjuvant activity; Muramyl dipeptide; Ovalbumin; Peptidoglycan monomer

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MURAMYL DIPEPTIDE; OVALBUMIN; PEPTIDOGLYCAN MONOMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TH1 CELL; TH2 CELL;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BREVIBACTERIUM; CELLS, CULTURED; FREUND'S ADJUVANT; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED CBA; MYCOBACTERIUM TUBERCULOSIS; OVALBUMIN; PEPTIDOGLYCAN; STRUCTURAL HOMOLOGY, PROTEIN; TH1-TH2 BALANCE;

EID: 77953231697     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.005     Document Type: Article

References (48)

1. Cox J.C., and Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine 15 3 (1997) 248-256
2. Schijns E.J.C.V. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12 (2000) 456-463
3. Aguilar J.C., and Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 25 (2007) 3752-3762
4. Ellouz F., Adam A., Ciobaru R., and Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59 (1974) 1317-1325
5. Puri A., Sahai R., Haq W., Zaidi A., Guru P.Y., Tripathi L.M., et al. Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster. Int Immunopharmacol 5 (2005) 937-946
6. Tamura M., Yoo Y.C., Yoshimatsu K., Yoshida R., Oka T., Ohkuma K., et al. Effects of muramyl dipeptide derivates as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 13 1 (1995) 77-82
7. Azuma I. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10 14 (1992) 1000-1006
8. Yoo Y.C., Yoshimatsu K., Koike Y., Hatsuse R., Yamanishi K., Tanishita O., et al. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine. Vaccine 16 (1998) 216-224
9. Krivorutchenko Y.L., Andronovskaja I.B., Hinkula J., Krivoshein Y.S., Ljungdahl-Ståhle E., Pertel S.S., et al. Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro. Vaccine 15 12-13 (1997) 1479-1486
10. Traub S., von Aulock S., Hartung T., and Hermann C. MDP and other muropeptides - direct and synergistic effects on the immune system. J Endotoxin Res 12 2 (2006) 69-85
11. Vidal V., Dewulf J., and Bahr G.M. Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide. Immunology 103 (2001) 479-487
12. Wardowska A., Dzierzbicka K., Trzonkowski P., and Mysliwski A. Immunomodulatory properties of new conjugates of muramyl dipeptide and nor-muramyl dipeptide with retro-tuftsin (Arg-Pro-Lys-Thr-OMe). Int Immunopharmacol 6 (2006) 1560-1568
13. Takada H., and Uehara A. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling. Curr Pharm Design 12 (2006) 4163-4172
14. Keglević D., Ladešić B., Tomašić J., Valinger Z., and Naumski R. Isolation procedure and properties of monomer unit from lysozyme digest of peptidoglycan complex excreted into the medium by penicillin-treated Brevibacterium divaricatum mutant. Biochim Biophys Acta 585 (1979) 273-281
15. Tomašić J., Sesartić L.J., Martin S.A., Valinger Z., and Ladešić B. Comparative susceptibility of a peptidoglycan monomer from Brevibacterium divaricatum and its anhydromuramyl analogue to hydrolysis with N-acetylmuramyl-l-alanine amidase. J Chromatogr 440 (1988) 405-414
16. Tomašić J., and Hršak I. Peptidoglycan monomer originating from Brevibacterium divaricatum - its metabolism and biological activities in the host. In: Schrinner E., Richmond M.H., Seibert G., and Schwarz U. (Eds). Surface Structures of Microorganisms and Their Interactions with the Mammalian Host (1987), VCH, Weinheim 113-121
17. Tomašić J., Hanzl-Dujmović I., Špoljar B., Vranešić B., Šantak M., and Jovičić A. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse. Vaccine 18 (2000) 1236-1243
18. Halassy Špoljar B., Čimbora T., Hanzl-Dujmović I., Dojnović B., Sabioncello A., Krstanović M., et al. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice. Vaccine 20 (2002) 3543-3550
19. Halassy B., Krstanović M., Frkanec R., and Tomašić J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 21 (2003) 971-976
20. Riveau G., Parant M., and Chedid L. Changes in rabbit febrile responses to muramyl dipeptide (MDP) after coupling to a synthetic carrier. J Leukoc Biol 36 (1984) 111-122
21. Krueger J.M., Karaszewski J.W., Davenne D., and Shoham S. Somnogenic muramyl peptides. Fed Proc 45 (1986) 2552-2555
22. Krueger J.M., Rosenthal R.S., Martin S.A., Walter J., Davenne D., Shoham S., et al. Bacterial peptidoglycans as modulators of sleep. I. Anhydro forms of muramyl peptides enhance somnogenic potency. Brain Res 403 (1987) 249-257
23. Martin S.A., Karnovsky M.L., Krueger J.M., Pappenheimer J.R., and Biemann K. Peptidoglycans as promoters of slow-wave sleep. I. Structure of the sleep-promoting factor isolated from human urine. J Biol Chem 259 (1984) 12652-12658
24. Krueger J.M., Karnovsky M.L., Martin S.A., Pappenheimer J.R., Walter J., and Biemann K. Peptidoglycans as promoters of slow-wave sleep. II. Somnogenic and pyrogenic activities of some naturally occurring muramyl peptides; correlations with mass spectrometric structure determination. J Biol Chem 259 (1984) 12659-12662
25. Stewart-Tull D.E.S. The assessment and use of adjuvants. In: Gregoriadis G., et al. (Ed). Vaccines (1991), Plenum press, New York 85-92
26. Stewart-Tull D.E.S. Recommendations for the assessment of adjuvants (immunopotentiators). In: Gregoriadis G., Allison A.C., and Poste G. (Eds). Immunological Adjuvants and Vaccines (1991), Plenum Publishing Corporation, New York 213-226
27. Adam A., Petit J.F., Lefrancier P., and Lederer E. Muramyl peptides. Chemical structure, biological activity and mechanisms of action. Mol Cell Biochem 41 (1981) 27-47
28. Krstanović M., Frkanec R., Vranešić B., Ljevaković D{stroke}., Šporec V., and Tomašić J. Reversed-phase high-performance liquid chromatographic method for the determination of peptidoglycan monomers and structurally related peptides and adamantyltripeptides. J Chromatogr B 773 (2002) 167-174
29. Habjanec L., Frkanec R., Halassy B., and Tomašić J. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice. J Liposome Res 16 (2006) 1-16
30. Habjanec L., Halassy B., and Tomašić J. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. Int Immunopharmacol 8 (2008) 717-724
31. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162 (1999) 3942-3949
32. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune response to a herpesvirus glycoprotein. Vaccine 21 (2002) 127-137
33. Chang J.C.C., Diveley J.P., Savary J.R., and Jensen F.C. Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliv Rev 32 (1998) 173-186
34. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11 3 (1993) 293-306
35. Magalhaes J.G., Fritz J.H., Le Bourhis L., Sellge G., Travassos L.H., Selvanantham T., et al. Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 181 (2008) 7925-7935
36. Moschos S.A., Bramwell V.W., Somavarapu S., and Alpar O. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 24 (2006) 1081-1086
37. Moschos S.A., Bramwell V.W., Somavarapu S., and Alpar O. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine 23 (2005) 1923-1930
38. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 11 (2003) 8869-8872
39. Girardin S.E., Travassos L.H., Herve M., Blanot D., Boneca I.G., Philpott D.J., et al. Peptidoglycan molecular requirements allowing detection by Nod 1 and Nod2. J Biol Chem 43 (2003) 41702-41708
40. Martinon F., Agostini L., Meylan E., and Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14 (2004) 1929-1934
41. Matzinger P. An innate sense of danger. Semin Immunol 10 (1998) 399-415
42. Benko S., Philpott D.J., and Girardin S.E. The microbial and danger signals that activate Nod-like receptors. Cytokine 43 3 (2008) 368-373
43. Takada H., Kawabata Y., Kawata S., and Kusumoto S. Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions to lipopolysaccharides. Infect Immun 64 (1996) 657-659
44. Nagao S., Takada H., Yagawa K., Kutsukake H., Shiba T., Kusumoto S., et al. Structural requirements of muramylpeptides for induction of necrosis at sites primed with Mycobacterium tuberculosis in guinea pigs. Infect Immun 55 (1987) 1279-1288
45. Miller L.H., Saul A., and Mahanty S. Revisiting Freund's incomplete adjuvant for vaccines in the developing world. Trends Parasitol 21 9 (2005) 412-414
46. Moreira L.O., Smith A.M., DeFreitas A.A., Qualls J.E., El Kasmi K.C., and Murray P.J. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 26 (2008) 5808-5813
47. Halassy B., Vdović V., Habjanec L., Lang Balija M., Gebauer B., Sabioncello A., et al. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits. Vaccine 25 (2007) 3475-3481
48. Habjanec L., Halassy B., Vdović V., Lang Balija M., and Tomašić J. Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants. Vet Immunol Immunopathol 121 (2008) 232-240